539 related articles for article (PubMed ID: 19125258)
1. Oncogenic osteomalacia: two case reports with surprisingly different outcomes.
Seijas R; Ares O; Sierra J; Pérez-Dominguez M
Arch Orthop Trauma Surg; 2009 Apr; 129(4):533-9. PubMed ID: 19125258
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic Osteomalacia From a Primary Phosphaturic Mesenchymal Tumor of the Toe: A Case Report.
Kim I; Rajani R
J Foot Ankle Surg; 2016; 55(2):294-8. PubMed ID: 25441266
[TBL] [Abstract][Full Text] [Related]
3. A rare case of multiple phosphaturic mesenchymal tumors along a tendon sheath inducing osteomalacia.
Arai R; Onodera T; Terkawi MA; Mitsuhashi T; Kondo E; Iwasaki N
BMC Musculoskelet Disord; 2017 Feb; 18(1):79. PubMed ID: 28193220
[TBL] [Abstract][Full Text] [Related]
4. Tumor-induced hypophosphatemic osteomalacia associated with tertiary hyperparathyroidism: a case report.
Tartaglia F; Minisola S; Sgueglia M; Blasi S; Brunelli D; Degli Effetti E; Maturo A; Cola A; Custureri F; Campana FP
G Chir; 2006; 27(1-2):9-13. PubMed ID: 16608626
[TBL] [Abstract][Full Text] [Related]
5. Tumor-induced osteomalacia with elevated fibroblast growth factor 23: a case of phosphaturic mesenchymal tumor mixed with connective tissue variants and review of the literature.
Hu FK; Yuan F; Jiang CY; Lv DW; Mao BB; Zhang Q; Yuan ZQ; Wang Y
Chin J Cancer; 2011 Nov; 30(11):794-804. PubMed ID: 22035861
[TBL] [Abstract][Full Text] [Related]
6. Tumor-induced osteomalacia: experience from a South American academic center.
González G; Baudrand R; Sepúlveda MF; Vucetich N; Guarda FJ; Villanueva P; Contreras O; Villa A; Salech F; Toro L; Michea L; Florenzano P
Osteoporos Int; 2017 Jul; 28(7):2187-2193. PubMed ID: 28341900
[TBL] [Abstract][Full Text] [Related]
7. Tumour-induced osteomalacia: An emergent paraneoplastic syndrome.
Alonso G; Varsavsky M
Endocrinol Nutr; 2016 Apr; 63(4):181-6. PubMed ID: 26718193
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of somatostatin receptor scintigraphy in the management of tumor-induced osteomalacia.
Duet M; Kerkeni S; Sfar R; Bazille C; Lioté F; Orcel P
Clin Nucl Med; 2008 Nov; 33(11):752-6. PubMed ID: 18936605
[TBL] [Abstract][Full Text] [Related]
9. Tumor-Induced Osteomalacia and the Importance of Plasma Fibroblast Growth Factor 23 as an Indicator: Diagnostic Delay Leads to a Suicide Attempt.
Seemann L; Padala SA; Mohammed A; Belayneh N
J Investig Med High Impact Case Rep; 2019; 7():2324709619895162. PubMed ID: 31850815
[TBL] [Abstract][Full Text] [Related]
10. Tumor-induced osteomalacia: successful treatment by radio-guided tumor surgery.
Harbeck B; Schöcklmann H; Seekamp A; Czech N; Mönig H
J Clin Rheumatol; 2009 Feb; 15(1):31-4. PubMed ID: 19125132
[TBL] [Abstract][Full Text] [Related]
11. Osteomalacia-Inducing Tumors of the Brain: A Case Report, Review and a Hypothesis.
Fathalla H; Cusimano M; Di Ieva A; Karamchandani J; Fung R; Kovacs K
World Neurosurg; 2015 Jul; 84(1):189.e1-5. PubMed ID: 25746588
[TBL] [Abstract][Full Text] [Related]
12. Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A).
Houang M; Clarkson A; Sioson L; Elston MS; Clifton-Bligh RJ; Dray M; Ranchere-Vince D; Decouvelaere AV; de la Fouchardiere A; Gill AJ
Hum Pathol; 2013 Dec; 44(12):2711-8. PubMed ID: 24060005
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic osteomalacia caused by a phosphaturic mesenchymal tumor of the oral cavity: a case report.
Yang IM; Park YK; Hyun YJ; Kim DY; Woo JT; Kim SW; Kim JW; Kim YS; Choi YK
Korean J Intern Med; 1997 Jan; 12(1):89-95. PubMed ID: 9159046
[TBL] [Abstract][Full Text] [Related]
14. Sinonasal hemangiopericytoma caused hypophosphatemic osteomalacia: A case report.
Li J; Huang Y; Yang F; Zhang Q; Chen D; Wang Q
Medicine (Baltimore); 2018 Dec; 97(52):e13849. PubMed ID: 30593185
[TBL] [Abstract][Full Text] [Related]
15. Osteomalacia induced by a phosphaturic mesenchymal tumor secreting fibroblast growth factor 23.
Nagae K; Uchi H; Ito T; Moroi Y; Oda Y; Furue M
Eur J Dermatol; 2015 Apr; 25(2):199-200. PubMed ID: 25788099
[No Abstract] [Full Text] [Related]
16. Oncogenic hypophosphataemic osteomalacia: biomarker roles of fibroblast growth factor 23, 1,25-dihydroxyvitamin D3 and lymphatic vessel endothelial hyaluronan receptor 1.
Hannan FM; Athanasou NA; Teh J; Gibbons CL; Shine B; Thakker RV
Eur J Endocrinol; 2008 Feb; 158(2):265-71. PubMed ID: 18230836
[TBL] [Abstract][Full Text] [Related]
17. Treatment and outcomes of tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors: retrospective review of 12 patients.
Zuo QY; Wang H; Li W; Niu XH; Huang YH; Chen J; You YH; Liu BY; Cui AM; Deng W
BMC Musculoskelet Disord; 2017 Sep; 18(1):403. PubMed ID: 28934935
[TBL] [Abstract][Full Text] [Related]
18. Persistent phosphaturic mesenchymal tumor causing tumor-induced osteomalacia treated with image-guided ablation.
Horng JC; Van Eperen E; Tutton S; Singh R; Shaker JL; Wooldridge AN
Osteoporos Int; 2021 Sep; 32(9):1895-1898. PubMed ID: 33655402
[TBL] [Abstract][Full Text] [Related]
19. [Osteomalacia due to phosphate deficiency caused by a tumor. Focus on FGF23 in physiology and clinic].
Westerberg PA; Linde T; Ljunggren O
Lakartidningen; 2012 Aug 8-21; 109(32-33):1414-6. PubMed ID: 22953430
[No Abstract] [Full Text] [Related]
20. Diagnostic utility of magnetic resonance imaging skeletal survey in a patient with oncogenic osteomalacia.
Fukumoto S; Takeuchi Y; Nagano A; Fujita T
Bone; 1999 Sep; 25(3):375-7. PubMed ID: 10495143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]